By Adriano Marchese
Glycomimetics shares fell in premarket trading after the company said a trial for cancer treatment Uproleselan missed its primary target.
Shares fell 6.7% to 16 cents.
The Rockville, Maryland-based clinical-stage biotechnology company said the Phase 2 study didn't show a statistically significant improvement for patients receiving the drug in combination with chemotherapy versus chemotherapy alone.
The study was performed on adults with newly diagnosed acute myeloid leukemia who were 60 years or older and fit for intensive chemotherapy.
Acute myeloid leukemia is form of blood cancer which grows abnormal cells rapidly, building up in the bone marrow and blood, and interfering with normal blood cell production.
Glycomimetics said it will transfer the trial data to the National Cancer Institute and the Alliance for Clinical Trials in Oncology to determine if the treatment may merit further study in future clinical trials.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 29, 2024 07:01 ET (11:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。